Cargando…

Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2

Chronic myeloid leukemia (CML) is a cytogenetic disorder resulting from formation of the Philadelphia chromosome (Ph), that is, the t(9;22) chromosomal translocation and the formation of the BCR-ABL1 fusion protein. Tyrosine kinase inhibitors (TKI), such as imatinib and nilotinib, have emerged as le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Jie, Romani, Julia, Zaborski, Margarete, MacLeod, Roderick A. F., Nagel, Stefan, Drexler, Hans G., Quentmeier, Hilmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859659/ https://www.ncbi.nlm.nih.gov/pubmed/24349524 http://dx.doi.org/10.1371/journal.pone.0083510

Ejemplares similares

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
por: Quentmeier, Hilmar, et al.
Publicado: (2011)

SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines
por: Quentmeier, Hilmar, et al.
Publicado: (2009)

CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation
por: Röhrs, Sonja, et al.
Publicado: (2010)

Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation
por: Quentmeier, Hilmar, et al.
Publicado: (2016)

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4)
por: Quentmeier, Hilmar, et al.
Publicado: (2012)

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2006)

Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing
por: Quentmeier, Hilmar, et al.
Publicado: (2016)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2019)

Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma
por: Quentmeier, Hilmar, et al.
Publicado: (2022)

Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma
por: Eberth, Sonja, et al.
Publicado: (2010)

Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib
por: Oruganti, Baswanth, et al.
Publicado: (2022)

Aberrant activity of NKL homeobox gene NKX3-2 in a T-ALL subset
por: Nagel, Stefan, et al.
Publicado: (2018)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway
por: Huang, Rui, et al.
Publicado: (2018)

Correction: Ectopic Expression of Homeobox Gene NKX2-1 in Diffuse Large B-Cell Lymphoma Is Mediated by Aberrant Chromatin Modifications
por: Nagel, Stefan, et al.
Publicado: (2013)

Ectopic Expression of Homeobox Gene NKX2-1 in Diffuse Large B-Cell Lymphoma Is Mediated by Aberrant Chromatin Modifications
por: Nagel, Stefan, et al.
Publicado: (2013)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma
por: Nagel, Stefan, et al.
Publicado: (2022)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Leukemia Cell Lines: In Vitro Models for the Study of Chronic Neutrophilic Leukemia
por: Drexler, Hans G., et al.
Publicado: (2021)

Propofol enhances BCR-ABL TKIs’ inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression
por: Tan, Zhimin, et al.
Publicado: (2017)

RBFOX2 and alternative splicing in B-cell lymphoma
por: Quentmeier, Hilmar, et al.
Publicado: (2018)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

A novel Bcr-Abl–mTOR–eIF4A axis regulates IRES-mediated translation of LEF-1
por: Tsai, Becky Pinjou, et al.
Publicado: (2014)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

There is a Scientific Need for the Right Leukemia-Lymphoma Cell Lines
por: Drexler, Hans G., et al.
Publicado: (2019)

The LL-100 panel: 100 cell lines for blood cancer studies
por: Quentmeier, Hilmar, et al.
Publicado: (2019)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Chromosome 11q23 aberrations activating FOXR1 in B-cell lymphoma
por: Pommerenke, C, et al.
Publicado: (2016)

Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
por: Genthon, Alexis, et al.
Publicado: (2020)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
por: Jiang, Liang, et al.
Publicado: (2021)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
por: Hughes, T P, et al.
Publicado: (2017)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

The LL-100 Cell Lines Panel: Tool for Molecular Leukemia–Lymphoma Research
por: Drexler, Hans G., et al.
Publicado: (2020)

Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma
por: Ehrentraut, Stefan, et al.
Publicado: (2016)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
por: Huo, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gt634upkr24ofsom4ehufa23oi